Biotech News

Absci Announces Positive Interim Phase 1 Data from the HEADLINE™ Trial of ABS-201, a Novel Antibody Targeting the Prolactin Receptor (PRLR)

Absci Corporation (ABSI)Absci Corporation2026-06-24 10:30 ESTClinical readout

Study medication appears well tolerated, with favorable safety data across all blinded single ascending dose (SAD) cohorts Estimated half-life of at least 65 days supports potential for ABS-201 targeted dosing interval of two or three injections over six-month period First multiple ascending dose

Absci Corporation

AI-Enabled Biologic Design Absci combines generative artificial intelligence with high-throughput synthetic biology to design and validate novel biologics. Its integrated platform repeatedly feeds laboratory results back into computational models. ABS-201 ABS-201 is a long-acting antibody against the prolactin receptor. Its...

Recent company news

ABSIAbsci Corporation2026-07-14 20:05 EST

Absci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026

ABSIAbsci Corporation2026-06-24 10:35 EST

Absci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investors

ABSIAbsci Corporation2026-06-24 10:30 EST